My SciELO
Services on Demand
Article
Indicators
- Cited by SciELO
Related links
- Similars in SciELO
Share
Vaccimonitor
Print version ISSN 1025-028X
Abstract
VALDES, Iliana et al. Relevant aspects of the use of Mycobacterium ´habana ´ as Tuberculosis vaccinal candidate. Vaccimonitor [online]. 2011, vol.20, n.3, pp. 34-39. ISSN 1025-028X.
The protective efficacy of current Tuberculosis vaccine (BCG) against pulmonary tuberculosis and reactivation is variable and inefficient. This is the reason of the urgent search of new prophylactic alternatives for disease control. Different strategies using Mycobacteriun tuberculosis auxotrophic mutants, recombinant BCG or non-tuberculous micobacteria are carried out taking advantage of the use of live vaccines. Experimental evidences demonstrate protection conferred by the vaccination with live, inactivated or protein fraction of Mycobacterium ´habana ´ TMC-5135. Protection seems to be related to few virulence signs in animal models. Experimental results place M. ´habana ´ among vaccine candidates against tuberculosis meeting the condition of a ¨classic¨ vaccine to mimic natural infection as close as possible inducing strong immune protective response without causing extensive disease.
Keywords : Mycobacterium ´habana ´; vaccine; tuberculosis.